CD8A and neoplasm: The most studied ligand, CCL16, has demonstrated an anti-cancer impact in mouse colon carcinoma and breast cancer through enhanced expression [111], attributable to an increase in CD4+ T cells, CD8+ T cells, and DC infiltration into the tumour, as well as in prostate cancer.